Figure 6.

Kaplan–Meier estimates of overall survival (A) and survival free of appropriate implantable cardioverter defibrillator therapy (B) in the primary prevention implantable cardioverter defibrillator cohort stratified by US vs. non-US sites. Out of 69 appropriate therapy events, 64 were implantable cardioverter defibrillator shocks and 5 were anti-tachycardia pacing. Time-zero reflects time of implantable cardioverter defibrillator implant during follow-up or first Sarcomeric Human Cardiomyopathy Registry site visit among participants who had a primary prevention implantable cardioverter defibrillator device implanted prior to first Sarcomeric Human Cardiomyopathy Registry site visit.